Search Results

You are looking at 1 - 10 of 140 items for :

  • "autologous stem cell transplantation" x
Clear All
Full access

Leona Holmberg and David G. Maloney

address these issues, and most studies have not included functional imaging. In addition, no unified acceptance of prognostic HL risk factors exists for comparing outcomes. Table 1 Results of Autologous Stem Cell Transplant in Hodgkin Lymphoma

Full access

Ashraf Badros

with neutral or somewhat favorable prognosis. 8 , 9 Deletion of chromosome 17p13, present in 10% of patients, confers poorer survival. Patients with this deletion who undergo HDT followed by autologous stem cell transplantation (ASCT) have

Full access

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger and Adam M. Petrich

to high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) at that time. She underwent consolidative radiation, during which she developed a scalp nodule and cervical lymphadenopathy, biopsy of which confirmed disease recurrence. She

Full access

Matthias Holdhoff, Maciej M. Mrugala, Christian Grommes, Thomas J. Kaley, Lode J. Swinnen, Carlos Perez-Heydrich and Lakshmi Nayak

-MTX regimen. More aggressive, potentially more effective therapies have been investigated that include high-dose chemotherapy (HDC) with or without autologous stem cell transplant (ASCT); however, these regimens are limited to fitter, and often younger

Full access

Jean-Luc Harousseau

Edited by Kerrin G. Robinson

-term survival of younger patients with multiple myeloma . Blood 2008 ; 111 : 2521 – 2526 . 9 Attal M Harousseau JL Facon T . Intergroupe Francophone du Myelome: single versus double autologous stem cell transplantation for multiple myeloma . N

Full access

Presenter : Shaji K. Kumar

survival (OS) with the triplet versus the doublet, which made it a definitive therapy for newly diagnosed disease. Figure 1. Approach to newly diagnosed multiple myeloma. Abbreviations: ASCT, autologous stem cell transplantation; Dara, daratumumab; DRd

Full access

Jean-Luc Harousseau and Philippe Moreau

; 93 : 55 – 65 . 9. Attal M Harousseau JL Facon T . Single versus double autologous stem-cell transplantation for multiple myeloma . N Engl J Med 2003 ; 349 : 2495 – 2502 . 10. Sonneveld P van der Holt B Segeren CM . Intensive

Full access

Saurabh Rajguru and Brad S. Kahl

to patients aged 65 years or younger without significant comorbidities ( Table 1 ). Examples of intensive therapies include chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) or the R-hyperCVAD (rituximab and

Full access

Shaji K. Kumar

asking whether patients with somewhat less risk can also benefit from early treatment. Newly Diagnosed Patients The key issue with newly diagnosed patients remains their eligibility for autologous stem cell transplant (ASCT). Transplant

Full access

Matthew Mei and George Somlo

than 80 years treated between 1973 and 2009. 1 Depth of response to therapy has long been associated with improved long-term outcomes. 2 Autologous stem cell transplantation (ASCT) was previously the only modality capable of inducing a very good